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in the Americas
The Burden of Lymphatic Filariasis (LF)
To date, close to 700 million  people 
in some of the poorest areas globally 
have received treatment to prevent 
one of the world’s most incapacitating 
diseases, lymphatic filariasis. 
Lymphatic filariasis (LF) is a disabling parasitic disease caused by microscopic worms that are 
spread from person-to-person by the 
bite of an infected mosquito. The adult 
worms live in the human lymphatic 
system and can cause lymphedema 
(swelling) affecting the legs, arms, 
or breasts. They can also cause 
hydrocele (severe fluid accumulation) 
affecting the genitalia of men. Chronic  
manifestations of lymphatic filariasis, 
which usually take place years after 
initial infection, can cause pain, severe 
and irreversible disfigurement, and stigmatization.
Lymphatic filariasis is one of the world’s neglected tropical diseases (NTDs), a group of infectious diseases 
affecting more than 1 billion people that is responsible for tremendous suffering and economic loss. LF is 
recognized as one of the most disabling and economically costly NTDs, as infection with the disease can lead 
to lower productivity and inability to work.
Over 120 million persons are infected with LF, a disease that can 
be eliminated
In 2000, the World Health Organization launched The Global Programme to Eliminate Lymphatic Filariasis, 
with a target elimination date of 2020.  This initiative is driven by a two-fold strategy to interrupt the spread 
of infection and reduce the suffering of persons already infected.  These efforts to interrupt transmission and 
improve disease management ensure that future generations will not suffer the same disability.
Infected persons can take a yearly dose of the medications albendazole plus either ivermectin or 
diethylcarbamazine (DEC) that kills the worms circulating in the blood. These medications, which are readily 
available through donations made by Merck, GlaxoSmithKline, and Eisai are distributed  to the entire at-risk 
population through mass drug administration (MDA). Within the first 9 years of the worldwide elimination 
program, 2.8 billion treatments for LF were delivered to more than 800 million people in 53 countries  
Although drug treatment may not reverse the symptoms of LF, better disease management, such as properly 
washing affected limbs, can improve a patient’s condition and prevent the progression of symptoms. Patients 
can carry out many of these activities with little training. Self-management to reduce suffering caused by LF 
includes regular washing and elevation of affected limbs, in addition to exercise. Surgery can cure hydrocele.
Interruption of LF transmission 
has been successful in Costa 
Rica, Suriname, and Trinidad 
and Tobago. 
The areas in red indicate the geographic 
distribution of lymphatic filariasis.
In the Americas, 11.3 million persons are at-risk for acquiring the disease. Transmission has been interrupted in Costa Rica, Suriname, and Trinidad and Tobago through focused public 
health efforts bringing treatment to affected communities. 
Currently, there is active transmission in only four countries in 
the Americas: Brazil, the Dominican Republic, Guyana, and Haiti. 
As of late 2009, nearly 5  million persons living in the Americas 
have received MDA.
Notable Achievements in 
the Americas
Although LF remains a public health problem in Brazil, the 
Dominican Republic, Guyana, and Haiti, much progress has 
been made toward elimination of the disease.
 • Brazil has eliminated transmission in several areas
 • Surveys carried out in the Dominican Republic that   
  monitor children for new LF infection suggest that      
  transmission has been interrupted in the largest   
  endemic area
 • MDA treatment is expanding in Haiti 
  - 4.5 million of the 8.6 million Haitians at-risk for LF  
   have received the benefit of annual treatment
  - 3 million Haitians have been treated since the   
   January 2010 earthquake 
	 • Disease management programs are operating in all   
  four endemic countries   
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In-country Support
In the Americas, CDC and its partners work alongside ministries of health to offer advice and expert 
consultation. Additionally, CDC and partner organizations develop monitoring and evaluation strategies 
and provide countries with technical support, as needed.  These organizations also work to carry out 
operational research and translate research into practice.
Operational Research
CDC’s operational research to improve programs includes work to understand compliance, transmission 
dynamics, and strategies to accelerate elimination. The following publications are recommended for 
further information:
• Addiss DG, Louis-Charles J, Roberts J, LeConte F, Wendt JM, et al. 2010. Feasibility and effectiveness of   
 basic lymphedema management in Leogane, Haiti, an area endemic for Bancroftian filariasis. PLoS Negl  
 Trop Dis. April 20; 4(4): e668
• Boyd A et al. 2010. A community-based study of factors associated with continuing transmission of   
 lymphatic filariasis in Leogane, Haiti. PLoS Negl Trop Dis. Mar 23;4(3):e640
• Grady CA et al. 2007. Endpoints for lymphatic filariasis programs. Emerg Infect Dis. April;13(4):608-10
Collaborations and Partnerships to Promote LF Elimination
CDC has built a number of successful partnerships with the following organizations:
September 2011
 • The Bill & Melinda Gates Foundation
 • CBM International
 • Eisai
 • GlaxoSmithKline
 • IMA World Health
 • Inter-American Development Bank
 
 • Merck
 • Pan American Health Organization
 • RTI International
 • The Task Force for Global Health
 • University of Notre Dame
 • United States Agency for International  
 Development (USAID)
Future Direction
 CDC and its team of partners are advancing elimination of LF from the Americas by:
 • Eliminating LF in Haiti by 2016
 • Developing tools and strategies to detect areas where transmission still exists in Haiti and Guyana
 • Utilizing mass media outlets in Haiti and Guyana to promote a national mobilization strategy that   
 supports MDA programs
 • Training workers to administer MDA in Haiti and Guyana
 • Distributing MDA to 100% of the geographic regions of Haiti and Guyana 
 • Evaluating the progress of MDA in Haiti and Guyana
 • Developing a surveillance strategy in Haiti and the Dominican Republic
CDC’s Response to Combat 
Lymphatic Filariasis in the Americas   
For more information on lymphatic filariasis, please visit   
www.cdc.gov/parasites/lymphaticfilariasis
800-CDC-INFO (800-232-4636)    •    TTY: 888-232-6348
